Cipla has no confirmed US launch yet among the blockbuster drugs on this tracker, holds FDA approval for 4 of them, and has 8 filed or in development. Those brands earned $92.7B in 2025. No other maker we follow is lined up to copy more of these drugs.
| Drug | Cipla's status | Other makers listed | 2025 brand sales |
|---|---|---|---|
| XareltoGeneric · Bayer / Johnson & Johnson · US LOE 2025 | FDA-approved 20 Feb 2026. Filed as InvaGen | 1 on sale · 17 approvedof 19 other makers listed | ≈$5.3B |
| FarxigaGeneric · AstraZeneca · US LOE 2026 | FDA-approved 6 Apr 2026 | 2 on sale · 12 approvedof 14 other makers listed | $8.4B |
| PomalystGeneric · Bristol Myers Squibb · US LOE 2026 | FDA-approved 31 Aug 2026 | 4 on sale · 5 approvedof 10 other makers listed | $2.7B |
| JardianceGeneric · Boehringer Ingelheim / Eli Lilly · US LOE 2029 | FDA-approved 22 Sep 2026. Filed as InvaGen | 0 on sale · 0 approvedof 1 other maker listed | ≈$9.9B |
| Drug | Cipla's status | Other makers listed | 2025 brand sales |
|---|---|---|---|
| LynparzaGeneric · AstraZeneca / Merck · US LOE 2027 | Filed with the FDA; in litigation, sued Jul 2026. Second filing sued Jul 2026 | 0 on sale · 1 approvedof 3 other makers listed | $3.3B |
| OtezlaGeneric · Amgen · US LOE 2028 | Filed with the FDA; settled 2021, terms confidential | 0 on sale · 5 approvedof 8 other makers listed | $2.3B |
| VyndaqelGeneric · Pfizer · US LOE 2031 | Filed with the FDA; settled Apr 2026; US entry allowed from 1 Jun 2031 | 0 on sale · 0 approvedof 3 other makers listed, plus unnamed filers | $6.4B |
| DescovyGeneric · Gilead · US LOE 2031 | Filed with the FDA; in litigation, sued Feb 2026. Earlier case settled in 2022; new challenge | 0 on sale · 2 approvedof 5 other makers listed | $2.8B |
| CabometyxGeneric · Exelixis · US LOE 2031 | Filed with the FDA; settled; US entry allowed from 1 Jan 2031 | 0 on sale · 3 approvedof 5 other makers listed | $2.1B |
| CalquenceGeneric · AstraZeneca · US LOE 2032 | Filed with the FDA; in litigation. Trial set for Apr 2027 | 0 on sale · 0 approvedof 1 other maker listed | $3.5B |
| BiktarvyGeneric · Gilead · US LOE 2036 | Filed with the FDA; settled Oct 2025; US entry allowed from 1 Apr 2036. Subject to standard acceleration provisions | 0 on sale · 0 approvedof 2 other makers listed | $14.3B |
| Drug | Cipla's status | Other makers listed | 2025 brand sales |
|---|---|---|---|
| KeytrudaBiosimilar · Merck · US LOE 2028 | Stage not disclosed. US partnership signed, Sep 2026 With Qilu |
0 on sale · 0 approvedof 9 other makers listed | $31.7B |
Copies not yet on sale, by the earliest year each could reach the US market: a settlement or court date where one is public, otherwise the brand's US exclusivity date. "Now" means that date has passed. Court rulings and new patents can move these.
Each row is a copy Cipla sells, holds an approval for, has filed, or is developing, for one of the 63 blockbuster drugs this site tracks. It is not Cipla's full portfolio. "Other makers listed" counts the other companies on the same drug's list: how many sell a copy and how many more hold an approval. Brand owners and the FDA don't always name every filer, so a list can be incomplete; the drug page says so where we know.
2025 sales are what each brand earned, the size of the market at stake. They are not Cipla's sales; several makers usually share a market once copies launch.
Every row is sourced on its drug's page: FDA Orange Book and Purple Book approvals, company releases and filings for launches, and court and company records for settlements. Company facts: TradingView.